| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/27/2002 | EP1181318A2 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules |
| 02/27/2002 | EP1181317A1 An integrin heterodimer and an alpha subunit thereof |
| 02/27/2002 | EP1181315A1 LAWSONIA DERIVED GENE AND RELATED FlgE POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES |
| 02/27/2002 | EP1181314A1 Polyepitopic proteinic fragments of the hiv nef protein, production and use thereof in vaccinations |
| 02/27/2002 | EP1181313A2 Peptides for vaccinating against human cmv |
| 02/27/2002 | EP1181312A1 Cytotoxic t-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy |
| 02/27/2002 | EP1181057A1 Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| 02/27/2002 | EP1181056A1 Lim mineralization protein splice variants |
| 02/27/2002 | EP1181054A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| 02/27/2002 | EP1181053A2 Use of soluble costimulatory molecules to enhance immune responses |
| 02/27/2002 | EP1181052A1 Protein a based binding domains with desirable activities |
| 02/27/2002 | EP1181051A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF IMMUNOLOGICALLY-MEDIATED DISEASES USING i MYCOBACTERIUM VACCAE /i |
| 02/27/2002 | EP1181050A1 Methods for preventing reactivation of latent virus and controlling virus replication |
| 02/27/2002 | EP1181040A1 Compositions of a-beta peptide and processes for producing same |
| 02/27/2002 | EP1181037A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 02/27/2002 | EP1181027A2 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 02/27/2002 | EP1181025A2 Molecular complexes presenting high affinity binding with respect to monocyte derived cells and their uses in therapy |
| 02/27/2002 | EP1180999A2 Recombinant vaccine against botulinum neurotoxin |
| 02/27/2002 | EP1180938A2 Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| 02/27/2002 | EP0939623B1 Oral delayed immediate release formulation and method of preparation therefor |
| 02/27/2002 | EP0865296B1 Influenza vaccine |
| 02/27/2002 | EP0836380B1 Fgf9 as a specific ligand for fgfr3 |
| 02/27/2002 | EP0827545B1 Retroviral vectors |
| 02/27/2002 | EP0787015B1 Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide |
| 02/27/2002 | EP0733114B1 Construction of pasteurella haemolytica mutants |
| 02/27/2002 | CN1337883A Tumor necrosis factor antagonists and their use in endometriosis |
| 02/27/2002 | CN1079832C Polypeptide for expressing virus of pig reproduction and respiration syndrome in same cell |
| 02/27/2002 | CN1079830C Methods and materials for treatment of individuals infected with intracellular infections agents |
| 02/27/2002 | CN1079677C Immunological tolerance-inducting agent |
| 02/26/2002 | US6350858 A polypeptide involved in controlling phosphate retention; diagnosis and therapy for chronic kidney failure, end stage kidney disease, uremic bone disease, and cancer |
| 02/26/2002 | US6350857 Fifty-four homologue (ffh) from streptococcus pneumoniae |
| 02/26/2002 | US6350854 Isolated 55 to 72 kDa protein which binds to prion proteins |
| 02/26/2002 | US6350612 Cloned and sequenced eco ri fragment of bordetella pertussis chromosomal dna with 4696 base pairs containing genes which code for five subunits of pertussis toxin or fragments thereof containing at least one gene which codes for subunit of toxin |
| 02/26/2002 | US6350603 Phosphodiesterase 10 |
| 02/26/2002 | US6350600 A polypeptide encoding transfer rna-methyl transferase; screening antibiotics, therapy for streptococcus pneumoniae infections; drug development |
| 02/26/2002 | US6350598 MurD |
| 02/26/2002 | US6350590 Tolerogenic fragments of natural allergens |
| 02/26/2002 | US6350581 Tumor-associated antigen |
| 02/26/2002 | US6350457 Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae |
| 02/26/2002 | US6350456 Composition comprising purified first and second polypeptides and physiologically acceptable carrier, wherein each polypeptide comprises immunogenic portion of mycobacterium tuberculosis antigen having specified amino acid sequence |
| 02/26/2002 | US6350454 Attenuated Pasteurella piscicida vaccine for fish |
| 02/26/2002 | US6350451 Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction |
| 02/26/2002 | US6350449 Immune composition comprising antibodies raised in mammal immunized with conjugate molecule comprising group b meningococcal polysaccharide having n-acetyl groups replaced with unsaturated acyl groups, covalently bound to protein |
| 02/26/2002 | US6350445 Method of treating cancer with a tumor cell line having modified cytokine expression |
| 02/26/2002 | CA2329474C Continuous low-dose cytokine infusion therapy |
| 02/26/2002 | CA2038030C Synthetic peptides which contain sequences from factor viia, and the use thereof |
| 02/26/2002 | CA2037709C Use of zinc calcium hydroxide, lecithin and pao as an adjuvant for antigen solutions, and antigen solutions treated with an adjuvant of this type |
| 02/21/2002 | WO2002014870A2 Use of antibodies against specific mhc-peptide complexes |
| 02/21/2002 | WO2002014522A1 Pyruvate:nadp+ oxidoreductase and uses thereof |
| 02/21/2002 | WO2002014516A1 Novel diagnostic agents of chronic or persistent chlamydial diseases and uses thereof |
| 02/21/2002 | WO2002014511A2 Regulation of human p2y1-like g protein-coupled receptor |
| 02/21/2002 | WO2002014504A1 Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
| 02/21/2002 | WO2002014503A2 Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies |
| 02/21/2002 | WO2002014499A2 Claudin polypeptides |
| 02/21/2002 | WO2002014487A2 Adeno-associated virus-mediated delivery of angiogenic factors |
| 02/21/2002 | WO2002014485A2 Kallikrein gene |
| 02/21/2002 | WO2002014481A1 Method of extensive culture of antigen-specific cytotoxic t cells |
| 02/21/2002 | WO2002014478A2 IMMUNOGENIC HBc CHIMER PARTICLES HAVING ENHANCED STABILITY |
| 02/21/2002 | WO2002014470A2 Expression of herstatin, an alternative her-2/neu product, in cells that express either p185her-2 or the egf receptor inhibits receptor activity and cell growth |
| 02/21/2002 | WO2002014370A1 Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof |
| 02/21/2002 | WO2002014369A2 Human kininogen d5 domain polypeptides and their use |
| 02/21/2002 | WO2002014362A2 A hepatitis c virus non-structural ns3/4a fusion gene |
| 02/21/2002 | WO2002014361A2 NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER |
| 02/21/2002 | WO2002014357A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/21/2002 | WO2002014355A2 Novel mitogen activated kinase |
| 02/21/2002 | WO2002014352A2 Therapeutic compounds for ovarian cancer |
| 02/21/2002 | WO2002014348A2 Glycoproteins and methods of use thereof |
| 02/21/2002 | WO2002013862A2 Method and composition for altering a b cell mediated pathology |
| 02/21/2002 | WO2002013861A2 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | WO2002013860A1 Stabilized antibody-containing preparations |
| 02/21/2002 | WO2002013858A1 Oral solid dose vaccine |
| 02/21/2002 | WO2002013857A2 A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof |
| 02/21/2002 | WO2002013856A2 W/o emulsion adjuvant compositions for vaccines |
| 02/21/2002 | WO2002013855A2 Vaccines containing ribavirin and methods of use thereof |
| 02/21/2002 | WO2002013845A2 Inflammation related g-protein coupled receptor |
| 02/21/2002 | WO2002013844A2 Specific autoimmune reactions against isomerised/optically inverted epitopes: application for treatment of autoimmune diseases |
| 02/21/2002 | WO2002013828A1 A retroviral immunotherapy |
| 02/21/2002 | WO2002013765A2 Malaria immunogen and vaccine |
| 02/21/2002 | WO2002013763A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001083698A3 Compositions and methods for inducing activation of dendritic cells |
| 02/21/2002 | WO2001081608A3 Viral vectors for use in monitoring hiv drug resistance |
| 02/21/2002 | WO2001080885A3 Equine protozoal myeloencephalitis vaccine |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001077149A3 Regulation of human cyslt2-like gpcr protein |
| 02/21/2002 | WO2001076626A3 Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants |
| 02/21/2002 | WO2001068849A8 Human ion channels |
| 02/21/2002 | WO2001068802A3 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 02/21/2002 | WO2001066747A8 Proteins named fctrx and nucleic acids encoding same |
| 02/21/2002 | WO2001066597A3 Inflammation-related gene |
| 02/21/2002 | WO2001064860A3 Recombinant influenza a viruses |
| 02/21/2002 | WO2001064246A3 Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| 02/21/2002 | WO2001059110A3 34p3d7: a tissue specific protein highly expressed in prostate cancer |
| 02/21/2002 | WO2001058484A3 Novel uses of mammalian ccr8 receptors and related reagents |
| 02/21/2002 | WO2001056602A3 Cd40 ligand adjuvant for respiratory syncytial virus |
| 02/21/2002 | WO2001055391A3 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| 02/21/2002 | WO2001054711A3 Use of neurotoxins for treating diabetes |
| 02/21/2002 | WO2001051008A3 Selective activation of a th1 or th2 lymphocyte regulated immune response |
| 02/21/2002 | WO2001044282A3 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 02/21/2002 | WO2001043693A3 Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef |